Natera, Inc. $NTRA Shares Purchased by Andra AP fonden

Andra AP fonden raised its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 193.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,737 shares of the medical research company's stock after purchasing an additional 54,537 shares during the period. Andra AP fonden owned 0.06% of Natera worth $16,547,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Robinhood Asset Management LLC acquired a new stake in shares of Natera in the 4th quarter valued at about $12,981,000. Systrade AG acquired a new position in Natera during the fourth quarter worth approximately $11,454,000. J. Safra Sarasin Holding AG acquired a new position in Natera during the fourth quarter worth approximately $2,825,000. UBS Group AG lifted its stake in Natera by 19.4% in the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company's stock valued at $100,538,000 after buying an additional 71,355 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Natera by 25.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company's stock valued at $11,476,000 after acquiring an additional 9,424 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research report on Friday. Royal Bank Of Canada initiated coverage on shares of Natera in a research note on Thursday, June 11th. They set an "outperform" rating and a $275.00 price target for the company. Robert W. Baird set a $265.00 price objective on shares of Natera in a research report on Friday, May 8th. Barclays dropped their price objective on shares of Natera from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 24th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Natera in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $267.83.

Insider Buying and Selling at Natera

In other news, Director Gail Boxer Marcus sold 11,000 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares of the company's stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Herm Rosenman sold 16,530 shares of the firm's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares of the company's stock, valued at $1,062,500. This trade represents a 79.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 178,872 shares of company stock worth $39,627,696. 5.05% of the stock is currently owned by company insiders.

Natera Stock Performance

NTRA stock opened at $267.18 on Wednesday. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04. The stock has a market capitalization of $38.26 billion, a PE ratio of -163.91 and a beta of 1.51. The company has a fifty day moving average of $236.50 and a 200-day moving average of $220.83.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.